Harvesting of peripheral blood The International Journal of Cell Cloning with the fenwal CS3000 PLUS® cell separator and a small volume collection chamber

Autor: JG Bender

Publikováno v: The International Journal of Cell Cloning. 10:79-81

Harvesting of peripheral blood The International Journal of Cell Cloning (PBSC) using the Fenwal CS3000 plus® and a small volume collection chamber (SVCC) that provides a product volume of 50 ml, was evaluated at three institutions on 21 normal indi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a4d47409a602e637051064d2128aab7
https://doi.org/10.1002/stem.5530100727

Oxidative Stress Associated With Increased Reactive Nitrogen Species Generation in the Liver and Kidney Caused by a Major Metabolite Accumulating in Tyrosinemia Type 1.

Autor: Bender JG; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil., Ribeiro RT; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil., Zemniaçak ÂB; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil., Palavro R; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil., Marschner RA; Departamento de Medicina Interna, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil., Wajner SM; Departamento de Medicina Interna, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil., Castro ET; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil., Leipnitz G; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.; Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil., Wajner M; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.; Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.; Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil., Amaral AU; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.; Programa de Pós-Graduação em Atenção Integral à Saúde (UNICRUZ/URI-Erechim/UNIJUÍ), Universidade Regional Integrada do Alto Uruguai e das Missões, Erechim, Rio Grande do Sul, Brazil.

Publikováno v: Cell biochemistry and function [Cell Biochem Funct] 2024 Dec; Vol. 42 (8), pp. e70010.

Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Autor: Pearson ADJ; ACCELERATE, c/o BLSI, Clos Chapelle-aux-Champs 30, Bte 1.30.30 BE-1200 Brussels, Belgium. Electronic address: andy1pearson@btinternet.com., Federico S; St Jude Children's Research Hospital, Memphis, TN, USA., Gatz SA; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Ortiz M; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lesa G; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Amsterdam, the Netherlands., Scobie N; Zoe4Life, Sullens, Switzerland., Gounaris I; Merck Serono Ltd (an affiliate of Merck KGaA, Darmstadt, Germany), Feltham, UK., Weiner SL; Children's Cancer Cause, Washington, DC, USA., Weigel B; University of Minnesota, Minneapolis, MN, USA., Unger TJ; Repare Therapeutics, Cambridge, MA, USA., Stewart E; St Jude Children's Research Hospital, Memphis, TN, USA., Smith M; National Cancer Institute, Bethesda, MD, USA., Slotkin EK; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Reaman G; US Food and Drug Administration, Silver Springs, MD, USA., Pappo A; St Jude Children's Research Hospital, Memphis, TN, USA., Nysom K; Righospitalet, Copenhagen, Denmark., Norga K; Antwerp University Hospital, Antwerp, Belgium; Paediatric Committee of the European Medicines Agency (EMA), Amsterdam, the Netherlands; Federal Agency for Medicines and Health Products, Brussels, Belgium., McDonough J; The Andrew McDonough B+ Foundation, Wilmington, DE, USA., Marshall LV; The Royal Marsden NHS Foundation Hospital, The Institute of Cancer Research, Sutton, Surrey, UK., Ludwinski D; Solving Kids' Cancer, New York, NY, USA., Ligas F; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Amsterdam, the Netherlands., Karres D; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Amsterdam, the Netherlands., Kool M; Hopp Children's Cancer Center, Heidelberg, Germany., Horner TJ; GSK, Collegeville, PA, USA., Henssen A; Charité Berlin, Berlin, Germany., Heenen D; KickCancer, Brussels, Belgium., Hawkins DS; Seattle Children's Hospital, Seattle, WA, USA; Children's Oncology Group, Seattle, WA, USA., Gore L; Children's Hospital Colorado, Aurora, CO, USA; University of Colorado School of Medicine, Aurora, CO, USA., Bender JG; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Galluzzo S; Italian Medicine Agency (AIFA), Rome, Italy., Fox E; St Jude Children's Research Hospital, Memphis, TN, USA., de Rojas T; ACCELERATE, c/o BLSI, Clos Chapelle-aux-Champs 30, Bte 1.30.30 BE-1200 Brussels, Belgium., Davies BR; AstraZeneca, Cambridge, UK., Chakrabarti J; Pfizer, Tadworth, UK., Carmichael J; The Royal Marsden NHS Foundation Hospital, The Institute of Cancer Research, Sutton, Surrey, UK., Bradford D; US Food and Drug Administration, Silver Springs, MD, USA., Blanc P; Imagine for Margo, Paris, France., Bernardi R; Genentech, a Member of the Roche Group, South San Francisco, CA, USA., Benchetrit S; National Agency for the Safety of Medicine and Health Products, Paris, France., Akindele K; The Dorcas Foundation, Lagos, Nigeria., Vassal G; ACCELERATE, c/o BLSI, Clos Chapelle-aux-Champs 30, Bte 1.30.30 BE-1200 Brussels, Belgium; Gustave Roussy Cancer Centre, Paris, France.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Sep; Vol. 190, pp. 112950. Date of Electronic Publication: 2023 Jun 21.

Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Autor: Pearson AD; ACCELERATE, Europe. Electronic address: andy1pearson@btinternert.com., Allen C; Texas Children Hospital, Houston, TX, USA; Baylor College of Medicine, Houston, TX, USA., Fangusaro J; Children's Healthcare of Atlanta, USA; Emory University School of Medicine, Atlanta, USA., Hutter C; St. Anna Children's Hospital, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria., Witt O; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Heidelberg University Hospital, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany., Weiner S; Children's Cancer Cause, Washington DC, USA., Reaman G; US Food and Drug Administration, Silver Springs, USA., Russo M; Novartis, New Jersey, USA., Bandopadhayay P; Department of Pediatrics, Harvard Medical School, Broad Institute, USA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, USA., Ahsan S; Merck & Co., Inc, Rahway, NJ, USA., Barone A; US Food and Drug Administration, Silver Springs, USA., Barry E; Day One Biopharmaceuticals, San Francisco, USA., de Rojas T; ACCELERATE, Europe., Fisher M; The Children's Hospital of Philadelphia, Philadelphia, USA., Fox E; St Jude Children's Research Hospital, Tennessee, USA., Bender JG; Memorial Sloan Kettering Cancer Centre, New York, USA., Gore L; Children's Hospital Colorado, USA; University of Colorado, USA., Hargrave D; UCL Great Ormond Street Institute of Child Health, London UK., Hawkins D; Seattle Children's Hospital, USA; Children's Oncology Group, Seattle, USA., Kreider B; BioMed Valley Discoveries, Kansas City, MO, USA., Langseth AJ; SpringWorks Therapeutics, Stamford, CT, USA., Lesa G; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Netherlands., Ligas F; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Netherlands., Marotti M; Boehringer Ingelheim, Germany., Marshall LV; The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK., Nasri K; Pierre-Fabre, Paris, France., Norga K; Antwerp University Hospital, Antwerp, Belgium; Paediatric Committee of the European Medicines Agency, (EMA), Netherlands; Federal Agency for Medicines and Health Products, Brussels, Belgium., Nysom K; Righospitalet, Copenhagen, Denmark., Pappo A; St Jude Children's Research Hospital, Tennessee, USA., Rossato G; F. Hoffmann-La Roche AG, Basel, Switzerland., Scobie N; Zoe4Life, Sullens, Switzerland., Smith M; National Cancer Institute, Maryland, USA., Stieglitz E; UCSF Benioff Children's Hospital San Francisco, USA., Weigel B; University of Minnesota, Minneapolis, USA., Weinstein A; Pediatric Brain Tumor Foundation, Atlanta, USA., Viana R; Alexion Pharmaceuticals, Zurich, Switzerland., Karres D; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Netherlands., Vassal G; ACCELERATE, Europe; Gustave Roussy Cancer Centre, Paris, France.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Dec; Vol. 177, pp. 120-142. Date of Electronic Publication: 2022 Oct 14.

Opportunities and Challenges in Drug Development for Pediatric Cancers.

Autor: Laetsch TW; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. laetscht@chop.edu., DuBois SG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts., Bender JG; Memorial Sloan Kettering Cancer Center, New York, New York., Macy ME; Children's Hospital Colorado and University of Colorado, Denver, Colorado., Moreno L; Division of Pediatric Hematology and Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Publikováno v: Cancer discovery [Cancer Discov] 2021 Mar; Vol. 11 (3), pp. 545-559. Date of Electronic Publication: 2020 Dec 04.